Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Evercore ISI Group Downgrades F5 to In-Line

Evercore ISI Group Downgrades F5 to In-Line

Evercore ISI Group analyst Amit Daryanani downgrades F5 (NASDAQ:FFIV) from Outperform to In-Line.

byBenzinga Newsdesk

October 11, 2022

1 minute read

Evercore ISI Group analyst Amit Daryanani downgrades F5 (NASDAQ:FFIV) from Outperform to In-Line.

Why Is Clinical-Stage Biotechnology Platform Company Humacyte Stock Gaining Friday?

By Nabaparna Bhattacharya

February 9, 2:06 PM

Humacyte's shares surge as FDA grants Priority Review to its BLA for Human Acellular Vessel (HAV) used in urgent arterial repair.

HUMA

Cathie Wood’s Key Portfolio Stock Surges Over 2% Premarket: What’s Going On?

By Shanthi Rexaline

January 19, 7:07 AM

Shares of streaming devices manufacturer Roku rose in premarket trading on Friday following a positive analyst action.

ARKW

Forma Therapeutics Hldgs Q2 EPS $(1.10) Misses $(0.99) Estimate

By Benzinga Newsdesk

August 5, 7:28 AM

Forma Therapeutics Hldgs (NASDAQ:FMTX) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(0.99) by 11.11 percent. This is a 19.57 percent decrease over losses of $(0.92) per

FMTX

Ethereum’s Bottom Against Bitcoin ‘Still Likely A Few Months Away,’ Predicts Crypto Analyst

By Khyathi Dalal

April 29, 1:58 PM

Prominent cryptocurrency analyst Benjamin Cowen predicted further bearish momentum for Ethereum (CRYPTO: ETH) to Bitcoi

BTC

Evercore ISI Group Downgrades F5 to In-Line

Related Posts

Why Is Clinical-Stage Biotechnology Platform Company Humacyte Stock Gaining Friday?

Cathie Wood’s Key Portfolio Stock Surges Over 2% Premarket: What’s Going On?

Forma Therapeutics Hldgs Q2 EPS $(1.10) Misses $(0.99) Estimate

Ethereum’s Bottom Against Bitcoin ‘Still Likely A Few Months Away,’ Predicts Crypto Analyst